LISINOPRIL: AN INNOVATION RESPONSE TO NEW CHALLENGES OF TIME
- Authors: Nikolaeva N.1
-
Affiliations:
- Omsk State Medical Academy
- Issue: Vol 24, No 12 (2013)
- Pages: 59-63
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115919
- ID: 115919
Cite item
Open Access
Access granted
Abstract
There is evidence that the hydrophilic angiotensin-converting enzyme inhibitor lisinopril may be used as a first-line drug to treat elderly hypertensive patients with significant comorbidity, including this drug as part of multicomponent therapy.
Keywords
Full Text
About the authors
N. Nikolaeva
Omsk State Medical Academy
Email: niknik.67@mail.ru
Candidate of Medical Sciences
References
- Николаев Н.А. Доказательная гипертензиология: количественная оценка результата антигипертензивной терапии / М.: Издательский дом «Академия Естествознания», 2008; 92 с.
- Патент РФ. 2352259 (51) МПК А61В 10/00 (2006.01) Способ количественной оценки результата антигипертензивной фармакотерапии [текст] / Николаев Н.А. № 2007140850/14; заявл. 02.11.2007; опубл. 20.04.2009, бюл. №11. 8 с.: ил.
- Патент РФ 2362488 (51) МПК А61В 10/00 (2006.01) Способ оценки экономической эффективности результата антигипертензивной фармакотерапии [текст] / Николаев Н.А.; № 2007140839/14; заявл. 02.11.2007; опубл. 27.07.2009; бюл. № 21; 7 с. : ил.
- Abbound H. Growth factors and diabetic nephropathy: an overview // Kidney Int. -1997; 52 (60): 3-6.
- Anderson A. Role of local and systemic angiotensin in diabetic renal disease. // Kidney Int. - 1997; 63: 107-10.
- Bakris G., Slataper R., Vicknair N. et al. ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic patients // J. Diabetes Complications. - 1994; 8 (1): 2-6.
- Border W., Noble N. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis // Hypertension. - 1998; 31 (1): 181-8.
- Chaturvedi N., Stevenson J., Fuller J. et al. Randomised placebo controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group // Lancet. -1997; 349: 1787-92.
- Cohen R. Endothelial dysfunction in diabetic vascular disease // Medicographia. -1997; 19: 157-61.
- Cohen R. Role of nitric oxide in vasomotor regulation. In: Loscalzo J., Vitra J.A., editors. Nitric oxide and cardiovascular system / Totowa, NJ: Humana Press, 2000; pp.105-22.
- Cohen R. The role of nitric oxide and other endothelium derived vasoactive substances in vascular disease // Cardiovasc. Dis. - 1995; 38: 5-28.
- Chodoff L. Lisinopril: a new ACE inhibitor for the treatment of hypertension and congestive heart failure // Mt. Sinai. J. Med. - 1990; 57: 169-71.
- Egido J. Vasoactive hormones and renal sclerosis. (Perspectives in Clinical Nephrology) // Kydney Int. - 1996; 49: 578-97.
- Erdos E. Angiotensin I-converting enzyme and the changes in our concepts through the years // Hypertension. -1990; 16: 363-70.
- Kafettz K. Renal impairment in the elderly: a review / J. R. Soc. Med. - 1983; 76: 398-401.
- Lorenzi M., Cagliero E. Pathobiology of endothelial and other vascular cells in diabetes mellitus // Diabetes. - 1991; 40: 653-9.
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker us Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // JAMA. - 2002; 288 (23): 2981-97.
- Nacane H., Miller F., Farasi F. et el. Gene transfer of endothelial nitric oxide synthase reduces angiotensin II-induced endothelial dysfunction // Hypertension. - 2000; 35 (2): 595-601.
- O’Donnel M., Rowe B., Lawson N. et а!. Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy // J. Hum. Hypertens. - 1993; 7 (4): 327-32.
- Parving H. Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy // J. Diabetes. Complications. - 1996; 10 (3): 133-5.
- Rostand S., Brown G., Kirk K. et al. Renal insufficiency in treated hypertensive patients // N. Eng. J. Med. - 1989; 320: 684-8.
- Walker W., Cutler J., Neuwirth R. et al. Blood pressure and renal function in the Multiple Factor Intervention Trial (MRFIT) // J. Hypertens. - 1990; 8 (3): 3.
- Vallejo S., Angulo J., Peiro C. et ак Highly glycated oxyhaemoglobin impairs nitric oxide relaxations in human mesenteric microvessels // Diabetologia. - 2000; 43: 83-90.
- Wattanapitayakul S., Weinstein D., Holycross B., Bauer J. Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders // FASEB J. - 2000; 14 (2): 271-8.
- Williams S., Goldfine A., Timimi F. et al. Acute hyperglycemia attenuates endothelium-dependent vasodilatation in humans in vivo // Circulation. -1998; 97: 1695-701.
Supplementary files
